+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID06894017

Study on Patient Preferences for Same-Day Dexamethasone Eye Injections in Both Eyes

Led by Rigshospitalet, Denmark · Updated on 2025-07-24

200

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying patient preferences for receiving intravitreal dexamethasone implant injections Ozurdex in both eyes on the same day in the same session. This approach is relevant for people with diabetic macular edema, macular edema from retinal vein occlusion, or noninfectious posterior uveitis. The study focuses on how personal and socio-economic factors influence patients choices and aims to improve patient experience and resource use in clinical care. The treatment being evaluated is the intravitreal dexamethasone implant Ozurdex given according to manufacturer recommendations. The study observes patients who have already received this implant in either eye, exploring their preferences regarding bilateral same-day injections. The research is observational and does not involve experimental treatment changes, focusing instead on gathering patient perspectives over about 9 months. Participants will provide information through questionnaires to identify their injection preferences and the reasons behind them. Researchers will also collect data on patient characteristics and socio-economic variables to understand differences between preference groups. The main outcome measured is the preference for bilateral injections during the study period. The study runs until early 2026 and is sponsored by Rigshospitalet, Denmark.

CONDITIONS

Brief Title

Patient Preferences on Same-day Bilateral Intravitreal Dexamethasone Injections

Research Team

L

Lena Michelle Mørup Andersen, MScN

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here